Norwegian Cancer Society invests in Lytix Biopharma AS
Lytix Biopharma is pleased to announce that the Norwegian Cancer Society has invested 6 million NOK in the Company as part of the prior private placement of 60 million NOK.
”We are proud that this competent and important institution has invested in Lytix. This as a further confirmation that our drug development within immune-oncology is on the right track, and we greatly appreciate the value of having the Norwegian Cancer Society in place as a significant investor”, says Håkan Wickholm, CEO of Lytix Biopharma.
“We have followed Lytix Biopharma closely over some years. Their technology within oncolytic peptides has been evaluated thoroughly. LTX-315 is a very interesting drug candidate and we found the time right to invest in Lytix Biopharma. We hope that the future development can bring clinical benefits for our cancer patients”, says Anne Lise Ryel, Secretary General of the Norwegian Cancer Society.